Omeros’ Omidria Revenues Grow 71 Percent

August 11, 2017: By Jon Swedien

OMEROSRevenues from Omidria grew 71 percent in Q2-2017 compared with Q2-2016, Seattle-based Omeros reported Aug. 8.

Omidria’s revenues during the quarter totaled $17.2 million, which marked a 40 percent increase over the drug’s revenues in Q1-2017, Omeros said. All of Omeros’ Q2-2017 revenues came from Omidria sales.

Omeros said units shipped by wholesalers in Q2-2017 increased 113 percent over Q2-2016 and 34 percent over Q1-2017.

Launched in April 2015, Omidria is intended for use during cataract surgery to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain. It is a combination of a mydriatic agent and a nonsteroidal anti-inflammatory agent that is added to irrigation solution used during IOL procedures.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023